PPAR agonists activate PPARA and/or PPARG receptors, improving inflammation, insulin sensitivity, hyperglycemia, and hyperlipidemia, which are the hallmarks of T2DM [107]. This evidence concerns the gene INS and type 2 diabetes mellitus.